2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 635

Factors Associated to Lack of Adherence to Subcutaneous Biological Medications in Patients with Rheumatoid Arthritis from Spain. Arco Study

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 563

Factors Associated with Cognitive Impairment in Korean Adults with Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - ARHP Poster

9:00AM-11:00AM: Abstract Number: 565

Factors Associated with Gastrointestinal Tolerance in Patients with Rheumatoid Arthritis and Methotrexate Daily Doses

Rheumatoid Arthritis – Clinical Aspects - ARHP Poster

9:00AM-11:00AM: Abstract Number: 779

Factors Determining Hydroxychloroquine Serum Levels in a Cohort of Chinese Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 1

Factors Predicting Likelihood of Remaining Positive for Rheumatoid Arthritis-Related Autoantibodies Following Autoantibody Screening

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 744

Factors Related to Blood Hydroxychloroquine Concentration in Patients with Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 14

Failure Predictors to Anti-Tumor Necrosis Antagonists in Patients with Chronic Arthritis: Results of a National Registry Biobadasar

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 87

Familiarity Vital for Telemedicine Uptake Among Parents of Pediatric Rheumatology Patients

Health Services Research - Poster I

9:00AM-11:00AM: Abstract Number: 887

Fatigue and Physical Functioning in Patients with Giant Cell Arteritis

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 892

FDG-PET CT Evaluation By Visual Grading Is Not Sufficiently Discriminative to Assess Disease Activity in Takayasu’s Arteritis Patients with ‘Persistent’ Disease

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 420

Feasibility of a Rheumatology Staff Protocol for Tobacco Cessation Counselling and Quit Line Electronic Referral

Quality Measures and Quality of Care - Poster I

9:00AM-11:00AM: Abstract Number: 48

Fibromyalgia Impact Is a Potential Mediator for the Associations of Self-Efficacy and Pain Catastrophizing with Physical Functioning in Persons with Fibromyalgia

Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes - Poster I: Basic Science Focus

9:00AM-11:00AM: Abstract Number: 490

First Report of Symptoms Using the Symptoms in Persons at Risk of Rheumatoid Arthritis (SPARRA) Questionnaire

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 163

Fluorescence Optical Imaging Reveals Distinct Patterns of Hand Joint Inflammation in Seropositive and Seronegative Early Rheumatoid Arthritis

Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies

9:00AM-11:00AM: Abstract Number: 883

Folate Receptor Beta and Endothelin Receptor Beta Macrophage Subtypes Are Differentially Expressed in the Vascular Compartments of the Intima and Media/Adventitia in Giant Cell Arteritis: A Pilot Study

Vasculitis - Poster I: Large Vessel Vasculitis and Polymyalgia Rheumatica

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].